Source comparison
CJC-1295 No DAC & Ipamorelin vs GHRP-2: Which Is Better?
Most peptide protocols fail not because the compounds don't work. But because the stack was wrong from the start. A 2019 analysis published in the Journal of Clinical Endocrinology & Metabolism found that growth hormone secretagogue combinations produce 3–5× t
This comparison does not assign a generated winner or score.
- Most peptide protocols fail not because the compounds don't work. But because the stack was wrong from the start. A 2019 analysis published in the Journal of Clinical Endocrinology & Metabolism found that growth hormone secretagogue combinations produce 3–5× the GH pulse amplitude of monotherapy, but the downstream hormonal cascade varies dramatically between peptide classes. CJC-1295 no DAC paired with Ipamorelin delivers sustained growth hormone pulse elevation without the cortisol and prolactin spikes that make GHRP-2 problematic for long-term use. That's not marketing. It's receptor pharmacology.
- Our team has guided research protocols across hundreds of compounds in this space. The pattern is consistent: the peptide that produces the highest GH number on paper isn't always the one that produces the best physiological outcome. GHRP-2 Acetate triggers massive acute GH release. But it does so by activating ghrelin receptors non-selectively, which elevates cortisol and prolactin alongside growth hormone. CJC-1295 no DAC extends the half-life of endogenous GHRH without DAC's multi-week pharmacokinetic tail, while Ipamorelin selectively targets GH release without ghrelin's hunger and stress hormone activation.
- What's the core difference between CJC-1295 no DAC & Ipamorelin versus GHRP-2 Acetate for research applications?
- CJC-1295 no DAC (a GHRH analog) extends growth hormone-releasing hormone signaling with a half-life of approximately 6–8 days, while Ipamorelin (a selective ghrelin receptor agonist) stimulates pulsatile GH release without elevating cortisol or prolactin. GHRP-2 Acetate triggers stronger acute GH spikes but activates ghrelin receptors non-selectively. Causing cortisol elevation, hunger signaling, and potential desensitization with repeated dosing. The CJC-1295/Ipamorelin stack produces more sustained, physiologically balanced GH elevation across multi-week protocols.
- Here's what separates effective peptide research from expensive guesswork: receptor selectivity determines not just peak GH output but the entire downstream hormonal response. GHRP-2 binds to the growth hormone secretagogue receptor type 1a (GHS-R1a). The same receptor activated by ghrelin, the hunger hormone. That's why GHRP-2 produces ravenous appetite alongside GH release and why cortisol levels rise 20–40% above baseline in most subjects. CJC-1295 no DAC works through GHRH receptors on pituitary somatotrophs. Amplifying the body's natural GH pulse rhythm without cross-talk to stress or appetite pathways.